Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2024-05-16 00:00:00 ET · period of report 2024-05-15 · accession 0000950170-24-061293 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2024-05-16 | 2024-05-15 | AMLX | Mazzariello Gina | CLO | S - Sale | $1.88 | -10.5K | 151.5K | -6% | -$19.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-15 | S | D | 10,455 | $1.88 | 151,477 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.82 to $1.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |